iBio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. iBio’s technology platform and facility capabilities are applicable to the development of monoclonal antibodies, biotherapeutics, ADCs, vaccines, and combination medical devices – and often provide significant time and value advantages over traditional approaches. iBio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic.

iBio’s team is comprised of knowledgeable molecular biologists, protein purification specialists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. The same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the iBio technology platform creates.

group hardhats 2018 04 11 10.01.00